Outcomes of Cyanoacrylate Tissue Adhesive Application in Corneal Thinning and Perforation.


Journal

Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 14 3 2019
medline: 18 6 2019
entrez: 14 3 2019
Statut: ppublish

Résumé

To report the outcomes of cyanoacrylate tissue adhesive (CTA) application in corneal thinning and perforation. A retrospective interventional case series of 137 patients receiving CTA for corneal thinning and perforation in 140 eyes between 2001 and 2018 at a single center was reviewed. Success rate and factors associated with glue failure were analyzed. Median age of the cohort was 63 years and 69 (50%) were women. One hundred fifteen patients (84%) had at least 1 systemic condition, 46 (34%) had autoimmune diseases. Eighty-nine eyes (64%) presented with perforation and 51 (36%) with thinning. The perforation/thinning was central/paracentral in 82 eyes (59%) and peripheral in 57 eyes (41%). Median size of perforation was 3.1 mm. Causes of perforation and thinning were microbial infection in 75 (55%), sterile melt in 49 (35%), laceration in 10, and keratoprosthesis melt in 8 eyes. Median glue retention was 58 days. Success rate of glue application (defined as intact globe without surgical intervention) was 72%, 61%, and 46% at 10, 30, and 90 days after glue application, respectively. Larger size of perforation/thinning, perforation (vs. thinning), and single glue application (vs. multiple) were correlated with higher failure rate. Systemic conditions, use of topical corticosteroid, etiologies, and location of perforation/thinning were not significantly correlated with glue failure. CTA application was moderately effective in stabilizing corneal perforation and thinning in the very short-term. Multiple applications are often required. Maintenance of globe integrity after glue application decreases with time and the need for surgical intervention remains high.

Identifiants

pubmed: 30865049
doi: 10.1097/ICO.0000000000001919
pmc: PMC6517072
mid: NIHMS1519627
doi:

Substances chimiques

Cyanoacrylates 0
Tissue Adhesives 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

668-673

Subventions

Organisme : NEI NIH HHS
ID : K12 EY016335
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Cornea. 2000 May;19(3):313-9
pubmed: 10832690
Ophthalmology. 2003 Feb;110(2):291-8
pubmed: 12578769
Cornea. 2003 Jul;22(5):405-8
pubmed: 12827043
J Cataract Refract Surg. 2004 Feb;30(2):287-90
pubmed: 15030802
Cornea. 2006 Apr;25(3):350-1
pubmed: 16633038
Ocul Surf. 2006 Jul;4(3):146-54
pubmed: 16900270
Cornea. 2007 Dec;26(10):1228-34
pubmed: 18043181
Expert Rev Med Devices. 2008 Jan;5(1):41-9
pubmed: 18095895
Am J Ophthalmol. 1991 Apr 15;111(4):466-72
pubmed: 2012149
Cornea. 2010 Sep;29(9):971-5
pubmed: 20539218
Cornea. 2010 Oct;29(10):1173-5
pubmed: 20622669
Cornea. 2012 Apr;31(4):465-6; author reply 466
pubmed: 21857507
Surv Ophthalmol. 2011 Nov-Dec;56(6):522-38
pubmed: 22117886
Cornea. 2013 May;32(5):e137-8
pubmed: 23407321
Cont Lens Anterior Eye. 2013 Aug;36(4):156-8
pubmed: 23623338
JAMA Ophthalmol. 2013 Apr;131(4):422-9
pubmed: 23710492
Am J Ophthalmol. 2014 Feb;157(2):327-333.e3
pubmed: 24315294
Clin Exp Ophthalmol. 2014 Nov;42(8):791-3
pubmed: 24533666
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25
pubmed: 26545825
Surv Ophthalmol. 1989 Jul-Aug;34(1):47-58
pubmed: 2678553
Br J Ophthalmol. 2017 May;101(5):634-639
pubmed: 27503392
Acta Biomater. 2018 Mar 15;69:31-41
pubmed: 29374600
Br J Ophthalmol. 2018 Oct;102(10):1328-1335
pubmed: 29581352
Am J Ophthalmol. 1987 Oct 15;104(4):437-8
pubmed: 3661662
Am J Ophthalmol. 1971 Sep;72(3):538-41
pubmed: 4936227
Arch Ophthalmol. 1968 Dec;80(6):705-9
pubmed: 5699321
Ophthalmology. 1983 Jun;90(6):610-5
pubmed: 6888854
Ophthalmology. 1994 Dec;101(12):1871-82
pubmed: 7997323
Ophthalmology. 1993 Feb;100(2):173-80
pubmed: 8437823
Doc Ophthalmol. 1996-1997;93(3):237-45
pubmed: 9550352
N Engl J Med. 1998 Jul 30;339(5):300-6
pubmed: 9696640

Auteurs

Jia Yin (J)

Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH